stockrowRelay Therapeutics, Inc.
RLAY Healthcare Biotechnology
Relay Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $15.4 million, up 53.4% from fiscal 2024.
- Revenue
- −95.4%
- EPS
- 0.00%
- Free cash flow
- +2.13%
Quarter to June 2026, against a year earlier
Follow RLAY
Alert me
Relay Therapeutics, Inc. (RLAY) Book value per share
Relay Therapeutics, Inc.'s book value per share at the end of fiscal 2025 was 3.3×, down 39.3% from 5.4× in fiscal 2024. At the end of the quarter to 30 June 2026 it was 4.4×. Over the past ten years it has ranged from −52.3× (fiscal 2019) to 17.9× (fiscal 2020); the current reading is higher than 25% of that period. Relay Therapeutics, Inc. ranks 166th of 611 Biotechnology companies by book value per share.
Book value per share, annual
Embed this chart
Annual newest first
| Period | Book value per share | Change |
|---|---|---|
| FY2025 | 3.3× | (39.30%) |
| FY2024 | 5.4× | (11.26%) |
| FY2023 | 6.1× | (27.54%) |
| FY2022 | 8.5× | (10.29%) |
| FY2021 | 9.4× | (47.31%) |
| FY2020 | 17.9× | — |
| FY2019 | −52.3× | — |
| FY2018 | 4.7× | — |
Quarterly newest first
| Period | Book value per share | Change |
|---|---|---|
| Jun 2026 | 4.4× | 22.88% |
| Mar 2026 | 3.6× | 8.05% |
| Dec 2025 | 3.3× | (6.25%) |
| Sep 2025 | 3.5× | (9.30%) |
| 25 more quarters | Free account |
Against its own ten years
Book value per share against peers
| Company | Book value per share |
|---|---|
| PBLS Parabilis Medicines, Inc. compare | 36.2× |
| IRON Disc Medicine, Inc. compare | 16.7× |
| XENE Xenon Pharmaceuticals Inc. compare | 12.5× |
| ACAD ACADIA Pharmaceuticals Inc. compare | 8.0× |
| TNGX Tango Therapeutics, Inc. compare | 6.8× |
| RLAY Relay Therapeutics, Inc. | 4.4× |
| EWTX Edgewise Therapeutics, Inc. compare | 4.2× |
| ABCL AbCellera Biologics Inc. compare | 2.9× |
| IOVA Iovance Biotherapeutics, Inc. compare | 0.0× |
What Book value per share is
BV per Share tells an investor how much of a company’s accounting net worth stands behind each share.
(Shareholders Equity (Total) ÷ Shares (Basic, Weighted))
More on RLAY
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Revenue growth
- Piotroski F-score
- Altman Z-score
- The full statement